Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Galmed Pharmaceuticals Ltd. is not a good value stock. Galmed Pharmaceuticals Ltd. is not a good growth stock. Galmed Pharmaceuticals Ltd. is a mediocre stock to choose.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the develop...

News

Galmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.com

Ticker Report StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the...\n more…

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

Ticker Report Equities researchers at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Get Free Report) in a report released on Friday. The brokerage set a "sell" rating on the...\n more…

Galmed Pharmaceuticals Reports Mid-Year Loss

TipRanks Financial Blog Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024, with research and...\n more…

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Zolmax StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the...\n more…

Galmed Pharmaceuticals Announces Reverse Stock Split

TipRanks Financial Blog Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has announced a reverse stock split at a ratio of 1-for-12, effective after market...\n more…

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

Ticker Report Research analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Get Free Report) in a research report issued to clients and investors on Thursday. The firm set...\n more…